期刊文献+

Efficacy of 1.2L polyethylene glycol plus ascorbic acid for bowel preparations 被引量:4

Efficacy of 1.2L polyethylene glycol plus ascorbic acid for bowel preparations
下载PDF
导出
摘要 BACKGROUND A low-volume polyethylene glycol(PEG) solution that combines ascorbic acid with PEG-based electrolyte solution(PEG-ASC) is gaining mainstream acceptance for bowel preparation due to reduced volume and improved taste.Although several reports showed that bowel preparation with PEG-ASC volume lower than 2.0 L with laxative agents could be an alternative to traditional preparation regimen, the cleansing protocols have not been fully investigated.AIM To evaluate the cleansing efficacy of 1.2 L PEG-ASC solution comparing with 2.0 L PEG electrolyte(PEG-ELS) for bowel preparations.METHODS A randomized, single-blinded, open-label, single-center, non-inferiority study was conducted. In total, 312 Japanese adult patients(aged > 18 years) who underwent colonoscopy were enrolled. Patients were randomly allocated to bowel lavage with either 1.2 L of PEG-ASC solution with at least 0.6 L of an additional clear fluid(1.2 L PEG-ASC group) or 2.0 L of PEG-ELS(PEG-ELS group). Then, 48 mg of sennoside was administered at bedtime on the day before colonoscopy, and the designated drug solution was administered at the hospital on the day of colonoscopy. Bowel cleansing was evaluated using the Boston Bowel Preparation Scale(BBPS). The volume of fluid intake and required time for bowel preparation were evaluated. Furthermore, compliance, patient tolerance,and overall acceptability were evaluated using a patient questionnaire, which was assessed using a visual analog scale.RESULTS In total, 291 patients(1.2 L PEG-ASC group, 148; PEG-ELS group, 143) completed the study. There was no significant difference in successful cleansing, defined as a BBPS score ≥ 2 in each segment, between the two groups(1.2 L PEG-ASC group, 91.9%; PEG-ELS group, 90.2%; 95%CI:-0.03-0.09). The required time for bowel preparation was significantly shorter(164.95 min ± 68.95 min vs 202.16 min± 68.69 min, P < 0.001) and the total fluid intake volume was significantly lower(2.23 L ± 0.55 L vs 2.47 L ± 0.56 L, P < 0.001) in the 1.2 L PEG-ASC group than in the PEG-ELS group. Palatability, acceptability of the volume of solution, and overall acceptability evaluated using a patient questionnaire, which was assessed by the visual analog scale, were significantly better in the 1.2 L PEG-ASC group than in the PEG-ELS group(7.70 cm ± 2.57 cm vs 5.80 cm ± 3.24 cm, P < 0.001). No severe adverse event was observed in each group.CONCLUSION The 1.2 L PEG-ASC solution was non-inferior to the 2.0 L PEG-ELS solution in terms of cleansing efficacy and had better acceptability among Japanese patients. BACKGROUND A low-volume polyethylene glycol(PEG) solution that combines ascorbic acid with PEG-based electrolyte solution(PEG-ASC) is gaining mainstream acceptance for bowel preparation due to reduced volume and improved taste.Although several reports showed that bowel preparation with PEG-ASC volume lower than 2.0 L with laxative agents could be an alternative to traditional preparation regimen, the cleansing protocols have not been fully investigated.AIM To evaluate the cleansing efficacy of 1.2 L PEG-ASC solution comparing with 2.0 L PEG electrolyte(PEG-ELS) for bowel preparations.METHODS A randomized, single-blinded, open-label, single-center, non-inferiority study was conducted. In total, 312 Japanese adult patients(aged > 18 years) who underwent colonoscopy were enrolled. Patients were randomly allocated to bowel lavage with either 1.2 L of PEG-ASC solution with at least 0.6 L of an additional clear fluid(1.2 L PEG-ASC group) or 2.0 L of PEG-ELS(PEG-ELS group). Then, 48 mg of sennoside was administered at bedtime on the day before colonoscopy, and the designated drug solution was administered at the hospital on the day of colonoscopy. Bowel cleansing was evaluated using the Boston Bowel Preparation Scale(BBPS). The volume of fluid intake and required time for bowel preparation were evaluated. Furthermore, compliance, patient tolerance,and overall acceptability were evaluated using a patient questionnaire, which was assessed using a visual analog scale.RESULTS In total, 291 patients(1.2 L PEG-ASC group, 148; PEG-ELS group, 143) completed the study. There was no significant difference in successful cleansing, defined as a BBPS score ≥ 2 in each segment, between the two groups(1.2 L PEG-ASC group, 91.9%; PEG-ELS group, 90.2%; 95%CI:-0.03-0.09). The required time for bowel preparation was significantly shorter(164.95 min ± 68.95 min vs 202.16 min± 68.69 min, P < 0.001) and the total fluid intake volume was significantly lower(2.23 L ± 0.55 L vs 2.47 L ± 0.56 L, P < 0.001) in the 1.2 L PEG-ASC group than in the PEG-ELS group. Palatability, acceptability of the volume of solution, and overall acceptability evaluated using a patient questionnaire, which was assessed by the visual analog scale, were significantly better in the 1.2 L PEG-ASC group than in the PEG-ELS group(7.70 cm ± 2.57 cm vs 5.80 cm ± 3.24 cm, P < 0.001). No severe adverse event was observed in each group.CONCLUSION The 1.2 L PEG-ASC solution was non-inferior to the 2.0 L PEG-ELS solution in terms of cleansing efficacy and had better acceptability among Japanese patients.
出处 《World Journal of Clinical Cases》 SCIE 2019年第4期452-465,共14页 世界临床病例杂志
关键词 Ascorbic acid BOWEL preparation COLONOSCOPY EFFICACY POLYETHYLENE GLYCOL TOLERABILITY Ascorbic acid Bowel preparation Colonoscopy Efficacy Polyethylene glycol Tolerability
  • 相关文献

参考文献1

二级参考文献84

  • 1Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA CancerJ Clin 2014; 64: 9-29 [PMID: 24399786 DOI: 10.3322/caac.21208].
  • 2Canadian Cancer Society, Statistics Canada, Public Health Agencyof Canada, Provincial/Territorial Cancer Registries. Canadian CancerStatistics 2014. Available from: URL: http://www.cancer.ca/statistics.
  • 3Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S,Coebergh JW, Comber H, Forman D, Bray F. Cancer incidence andmortality patterns in Europe: estimates for 40 countries in 2012. EurJ Cancer 2013; 49: 1374-1403 [PMID: 23485231 DOI: 10.1016/j.ejca.2012.12.027].
  • 4Winawer SJ, Zauber AG, Ho MN, O'Brien MJ, Gottlieb LS,Sternberg SS, Waye JD, Schapiro M, Bond JH, Panish JF. Preventionof colorectal cancer by colonoscopic polypectomy. The NationalPolyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981[PMID: 8247072].
  • 5Shaukat A, Mongin SJ, Geisser MS, Lederle FA, Bond JH, MandelJS, Church TR. Long-term mortality after screening for colorectalcancer. N Engl J Med 2013; 369: 1106-1114 [PMID: 24047060 DOI:10.1056/NEJMoa1300720].
  • 6American Cancer Society. Cancer Facts & Figures 2015. Atlanta:American Cancer Society; 2015. Available from: URL: http://www.cancer.org/acs/groups/content/@editorial/documents/document/acspc-044552.pdf.
  • 7Bressler B, Paszat LF, Vinden C, Li C, He J, Rabeneck L.Colonoscopic miss rates for right-sided colon cancer: a populationbasedanalysis. Gastroenterology 2004; 127: 452-456 [PMID:15300577].
  • 8Kaminski MF, Regula J, Kraszewska E, Polkowski M,Wojciechowska U, Didkowska J, Zwierko M, Rupinski M, NowackiMP, Butruk E. Quality indicators for colonoscopy and the riskof interval cancer. N Engl J Med 2010; 362: 1795-1803 [PMID:20463339 DOI: 10.1056/NEJMoa0907667].
  • 9Corley DA, Jensen CD, Marks AR, Zhao WK, Lee JK, DoubeniCA, Zauber AG, de Boer J, Fireman BH, Schottinger JE, QuinnVP, Ghai NR, Levin TR, Quesenberry CP. Adenoma detection rateand risk of colorectal cancer and death. N Engl J Med 2014; 370:1298-1306 [PMID: 24693890 DOI: 10.1056/NEJMoa1309086].
  • 10Baxter NN, Sutradhar R, Forbes SS, Paszat LF, Saskin R,Rabeneck L. Analysis of administrative data finds endoscopistquality measures associated with postcolonoscopy colorectalcancer. Gastroenterology 2011; 140: 65-72 [PMID: 20854818 DOI:10.1053/j.gastro.2010.09.006].

共引文献4

同被引文献30

引证文献4

二级引证文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部